

Clinical Trials Information #55

Principal Investigator	James Markmann, MD, PhD and Michael Rickels, MD
Study Title:	A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-264 in Subjects With Type 1 Diabetes Mellitus

Purpose:

To evaluate the safety and effectiveness of VX-264, a surgically implanted device containing stem cell derived islet cells for the treatment of Type 1 Diabetes.

Brief Description

VX-264 is surgically implanted below the muscle in the abdomen. It contains a mixture of cells made from human embryonic stem cells that can make insulin and other hormones like glucagon that are usually made in the pancreatic islets.

Eligibility

18-65 years old with Type 1 Diabetes

Hgb A1C 7% to 9.5%

Blood Type A or AB

Compensation (if applicable)

Travel and hotel costs will be covered

Which section would you like the trial listed under?	Rodebugh Center Trials
---	------------------------

Name	Mary Kaminski
-------------	---------------

Phone	(215) 662-2037
--------------	----------------

Email:	mary.kaminski@pennmedicine.upenn.edu
---------------	--------------------------------------